Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ex-Astra USA CEO Bildman pleads guilty to filing false U.S. income tax returns.

  • News

Executive Summary

EX-ASTRA USA CEO BILDMAN TO SERVE 21 MONTHS IN PRISON FOR TAX FRAUD under a plea bargain entered in Boston federal court Jan. 26. Former Astra USA CEO Lars Bildman pled guilty to three counts of filing false tax returns for the years 1993, 1994 and 1995. The plea agreement was provisionally accepted by Boston federal court Judge Nathaniel Gorton; sentencing is set for April 8. In addition to a 21-month prison sentence followed by three years of supervised release, Bildman will pay a $30,000 fine and reimburse the Internal Revenue Service for back taxes. Prosecutors dropped 32 other counts against Bildman involving mail and wire fraud.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS031584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By